{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:41:01Z","timestamp":1792690861061,"version":"4.5.0"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Crooke cell adenomas (CCA) are a rare and aggressive subtype of corticotrope tumors, with a prevalence of less than 1% pituitary adenomas, commonly manifest as Cushing\u2019s syndrome. We present the case of a 62-year-old male with progressive lower limb oedema, hypertension, and severe refractory hypokalemia. In this case, severe hypercortisolism was identified with the presence of a pituitary microadenoma of 9\u00d76 mm and adrenal bilateral hyperplasia. Ectopic hypercortisolism was discarded after further evaluation. The patient was taken to a transsphenoidal endoscopic resection with complete resolution of symptoms. Histopathological and microscopic studies revealed findings consistent with Crooke cells compatible with Crooke cell adenoma. This tumor subtype exhibits a heterogeneous clinical presentation and is infrequently reported in the literature. Consequently, it represents an unpredictable clinical entity with a variable medical course.<\/jats:p>","DOI":"10.3389\/fmed.2025.1468727","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T05:25:12Z","timestamp":1750829112000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Case Report: Refractory hypokalemia as a clinical manifestation of Crooke\u2019s cell adenoma"],"prefix":"10.3389","volume":"12","author":[{"given":"Laura","family":"Kattah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizeth","family":"Bustamante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Sanabria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johana","family":"Salazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,25]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12022-022-09703-7","article-title":"Overview of the 2022 WHO classification of pituitary tumors","volume":"33","author":"Asa","year":"2022","journal-title":"Endocr Pathol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s11596-022-2673-6","article-title":"Overview of the 2022 WHO classification of pituitary adenomas\/pituitary neuroendocrine tumors: clinical practices, controversies, and perspectives","volume":"42","author":"Wan","year":"2022","journal-title":"Curr Med Sci"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"947085","DOI":"10.3389\/fendo.2022.947085","article-title":"Prevalence and clinical characteristics of Crooke's cell adenomas in 101 patients with T-PIT-positive pituitary adenomas: case series and literature review","volume":"13","author":"Zhu","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12902-021-00761-2","article-title":"Apoplexy of Crooke cell tumour leading to the diagnosis of severe Cushing disease; a case report","volume":"21","author":"de Silva","year":"2021","journal-title":"BMC Endocr Disord"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e898","DOI":"10.1016\/j.wneu.2020.03.152","article-title":"Gamma knife radiosurgery in patients with Crooke cell adenoma","volume":"138","author":"Snyder","year":"2020","journal-title":"World Neurosurg"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"luad114","DOI":"10.1210\/jcemcr\/luad114","article-title":"Pituitary crooke cell adenoma: two cases of an aggressive pituitary adenoma","volume":"1","author":"Taiwo","year":"2023","journal-title":"JCEM Case Rep"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"e754","DOI":"10.1016\/j.wneu.2021.11.049","article-title":"Functioning Crooke cell adenomas: case series and literature review","volume":"158","author":"Giraldi","year":"2022","journal-title":"World Neurosurg"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1113\/jphysiol.2014.282871","article-title":"Cushing's syndrome: from physiological principles to diagnosis and clinical care","volume":"593","author":"Raff","year":"2015","journal-title":"J Physiol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S2213-8587(16)00086-3","article-title":"Complications of Cushing's syndrome: state of the art","volume":"4","author":"Pivonello","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3389\/fendo.2017.00043","article-title":"Effects of chronic ACTH excess on human adrenal cortex","volume":"8","author":"Bertagna","year":"2017","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1227\/NEU.0000000000000657","article-title":"Crooke's cell tumors of the pituitary","volume":"76","author":"Di Ieva","year":"2015","journal-title":"Neurosurgery"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1007\/s11102-011-0363-7","article-title":"Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature","volume":"15","author":"Annamalai","year":"2012","journal-title":"Pituitary"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/587893","article-title":"Temozolomide therapy for aggressive pituitary tumors: results in a small series of patients from Argentina","volume":"2015","author":"Bruno","year":"2015","journal-title":"Int J Endocrinol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1507\/endocrj.EJ18-0547","article-title":"Successful reduction of ACTH secretion in a case of intractable Cushing's disease with pituitary Crooke's cell adenoma by combined modality therapy including temozolomide","volume":"66","author":"Tanaka","year":"2019","journal-title":"Endocr J"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"526","DOI":"10.5603\/EP.2016.0060","article-title":"Long-term complete remission of Crooke's corticotropinoma after temozolomide treatment","volume":"67","author":"Kurowska","year":"2016","journal-title":"Endokrynol Pol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ccr3.39","article-title":"Long-term remission in an aggressive Crooke cell adenoma of the pituitary, 18 months after discontinuation of treatment with temozolomide","volume":"2","author":"Asimakopoulou","year":"2014","journal-title":"Clin Case Reports"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1530\/EJE-09-0414","article-title":"High incidence of low O(6)-methylguanine DNA methyltransferase expression in invasive macroadenomas of Cushing\u2019s disease","volume":"161","author":"Takeshita","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1210\/JC.2015-2493","article-title":"Crooke's changes in Cushing's syndrome depends on degree of hypercortisolism and individual susceptibility","volume":"100","author":"Oldfield","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1385\/EP:13:3:245","article-title":"Crooke's hyalinization in silent corticotroph adenoma: report of two cases","volume":"13","author":"Roncaroli","year":"2002","journal-title":"Endocr Pathol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1468727\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T05:25:13Z","timestamp":1750829113000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1468727\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,25]]},"references-count":19,"alternative-id":["10.3389\/fmed.2025.1468727"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1468727","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,25]]},"article-number":"1468727"}}